These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
148 related articles for article (PubMed ID: 825590)
21. Clinical and laboratory studies with amikacin in newborns, infants, and children. Trujillo H; Manotas R; Londono R; Ramirez JI; Uribe A; De Vidal EL; Agudelo N J Infect Dis; 1976 Nov; 134 SUPPL():S406-11. PubMed ID: 993632 [TBL] [Abstract][Full Text] [Related]
22. [Amikacin in the treatment of hospital infections of the urinary tract caused by gram-negative bacilli resistant to gentamicin. Microbiological and clinical aspects]. Romoli E; Di Leonardo F; Giordano G; De Felice M; Cerquetti F; Vonmoos A Minerva Urol; 1981; 33(2):85-90. PubMed ID: 7322100 [No Abstract] [Full Text] [Related]
23. Controlled comparison of amikacin and gentamicin. Smith CR; Baughman KL; Edwards CQ; Rogers JF; Lietman PS N Engl J Med; 1977 Feb; 296(7):349-53. PubMed ID: 319355 [TBL] [Abstract][Full Text] [Related]
24. Susceptibility of current clinical isolates of Pseudomonas aeruginosa and enteric gram-negative bacilli to amikacin and other aminoglycoside antibiotics. Dámaso D; Moreno-López M; Martínez-Beltrán J; García-Iglesias MC J Infect Dis; 1976 Nov; 134 SUPPL():S394-90. PubMed ID: 825591 [TBL] [Abstract][Full Text] [Related]
25. Clinical experience with amikacin, a new aminoglycoside antibiotic. Theron FP; De Kock MA S Afr Med J; 1977 May; 51(21):746-8. PubMed ID: 327583 [TBL] [Abstract][Full Text] [Related]
26. Amikacin therapy for serious gram-negative bacillary infections. Meyer RD; Lewis RP; Carmalt ED; Finegold SM Ann Intern Med; 1975 Dec; 83(6):790-800. PubMed ID: 1200524 [TBL] [Abstract][Full Text] [Related]
27. Serum concentrations and inhibitory ratios during amikacin therapy of gram-negative infections. Farchione LA; Chudzik GM J Clin Pharmacol; 1978; 18(8-9):432-8. PubMed ID: 690253 [TBL] [Abstract][Full Text] [Related]
28. Amikacin for treatment of infections in patients with malignant diseases. Bodey GP; Rodriguez V; Valdivieso M; Feld R J Infect Dis; 1976 Nov; 134 SUPPL():S421-7. PubMed ID: 993633 [TBL] [Abstract][Full Text] [Related]
29. Treatment of pediatric infections with amikacin as first-line aminoglycoside. Shulman ST; Yogev R Am J Med; 1985 Jul; 79(1A):43-50. PubMed ID: 4025367 [TBL] [Abstract][Full Text] [Related]
30. Comparison of amikacin and tobramycin in the treatment of infection in patients with cancer. Feld R; Valdivieso M; Bodey GP; Rodriguez V J Infect Dis; 1977 Jan; 135(1):61-6. PubMed ID: 401853 [TBL] [Abstract][Full Text] [Related]
31. Comparative kinetics and efficacy of amikacin administered once or twice daily in the treatment of systemic gram-negative infections. Giamarellou H; Yiallouros K; Petrikkos G; Moschovakis E; Vavouraki E; Voutsinas D; Sfikakis P J Antimicrob Chemother; 1991 May; 27 Suppl C():73-9. PubMed ID: 1906864 [TBL] [Abstract][Full Text] [Related]
32. Comparative effectiveness of combinations of amikacin with penicillin G and amikacin with carbenicillin in gram-negative septicemia: double-blind clinical trial. Klastersky J; Hensgens C; Meunier-Carpentier F J Infect Dis; 1976 Nov; 134 SUPPL():S433-40. PubMed ID: 792359 [TBL] [Abstract][Full Text] [Related]
33. [Treatment of hospital-acquired urinary infections with amikacin (author's transl)]. Weidner W; Nöske HD; Sziegoleit A; Schröder R; Leidenfrost U Med Klin; 1979 Jul; 74(27):1071-6. PubMed ID: 470792 [TBL] [Abstract][Full Text] [Related]
34. [Amikacin resistance of clinical strains of Enterobacteriaceae and Pseudomonas]. Moreva TV; Anisimova LA; Erova TE; Boronin AM Antibiot Khimioter; 1992 Apr; 37(4):25-8. PubMed ID: 1417311 [TBL] [Abstract][Full Text] [Related]
35. Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Winston DJ; Barnes RC; Ho WG; Young LS; Champlin RE; Gale RP Am J Med; 1984 Sep; 77(3):442-50. PubMed ID: 6475984 [TBL] [Abstract][Full Text] [Related]
36. Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies. Martino P; Venditti M; Petti MC; Mandelli F; Serra P Infection; 1985; 13(3):125-9. PubMed ID: 3928495 [TBL] [Abstract][Full Text] [Related]
37. Suceptibility of aminoglycoside-resistant gram-negative bacilli to amikacin: delineation of individual resistance patterns. Acar JF; Witchitz JL; Goldstein F; Talbot JN; Le Goffic F J Infect Dis; 1976 Nov; 134 SUPPL():S280-5. PubMed ID: 825587 [TBL] [Abstract][Full Text] [Related]
38. [Effectiveness of using aminoglycoside antibiotics in septicemia and urinary tract infections in newborn infants]. Sentsova TB; Bombardirova EP; Mamedkulieva DT; Bekmukhambetova ER Antibiot Khimioter; 1990 Oct; 35(10):50-2. PubMed ID: 2126174 [TBL] [Abstract][Full Text] [Related]
39. [Experimental study of the antibacterial activity and chemotherapeutic effectiveness of amikacin sulfate]. Lobuseva AN; Kuznetsova SM; Samoĭlova LN Antibiot Med Biotekhnol; 1985 Oct; 30(10):776-80. PubMed ID: 4091515 [TBL] [Abstract][Full Text] [Related]
40. Amikacin therapy of severe infections produced by gram-negative bacilli resistant to gentamicin. Valdivieso M; Bodey GP Am J Med Sci; 1977; 273(2):177-84. PubMed ID: 860733 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]